Serum concentrations of neopterin, soluble interleukin 2 receptor, and soluble tumor necrosis factor receptor in Wegener's granulomatosis

Journal of Rheumatology

Volumn 24, Issue 4, 1997, Pages 666-670

  Nassonov, Eugeney L ^f   Samsonov, Mikhail Y ^a   Tilz, Gernot P ^b   Beketova, Tatiana V ^f   Semenkova, Eugenija N ^c   Baranov, Andrey ^d   Wachter, Helmut ^f   Fuchs, Dietmar ^e  

^a Federal State Institution   (Russian Federation)

^b UNIVERSITY OF GRAZ   (Austria)

^c I M SECHENOV FIRST MOSCOW STATE MEDICAL UNIVERSITY   (Russian Federation)

^d Yaroslavl Medical University   (Russian Federation)

^e UNIVERSITY OF INNSBRUCK   (Austria)

^f NONE

Author keywords

Neopterin; Soluble cytokine receptors; Wegener's granulomatosis

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; INTERLEUKIN 2 RECEPTOR; NEOPTERIN; PREDNISOLONE; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; WEGENER GRANULOMATOSIS;

ADULT; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; BIOPTERIN; C-REACTIVE PROTEIN; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPTERIN; RECEPTORS, INTERLEUKIN-2; RECEPTORS, TUMOR NECROSIS FACTOR; WEGENER GRANULOMATOSIS;

EID: 0030960720     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Hoffman GS, Kerr GS, Leavitt RY, et al: Wegener granulomatosis: An analysis of 158 patients. Ann Intern Med 1992;116:488-98.
2. Van der Woude FJ, Rasmussen N, Lobatto S, et al: Autoantibodies against neutrophils and monocytes: Tool for diagnosis and marker of disease activity in Wegener's granulomatosis. Lancet 1985;425-9.
3. Jennings JG, Chang L, Savige JA, et al: Anti-proteinase 3 antibodies, their characterization and disease association. Clin Exp Immunol 1994;95:251-6.
4. Gross WL, Schmitt WH, Csernok E: ANCA associated disease: Immunodiagnostic and pathogenetic aspects. Clin Exp Immunol 1993;91:1-12.
5. Robertson CR, McCallum RM: Changing concepts in pathophysiology of the vasculitides. Curr Opin Rheumatol 1994;6:3-10.
6. Hooks JJ, Jordan CW, Cupps T, Moutsopoulos HM, Fauci AS, Notkin AL: Multiple interferons in the circulation of patients with systemic lupus erythematosus and vasculitis. Arthritis Rheum 1982;25:396-400.
7. Grau GE, Roux-Lombard P, Gysler C, et al: Serum cytokine changes in systemic vasculitis. Immunology 1989;68:196-8.
8. Roux-Lombard P, Lin HC, Peter JB, Dayer JM: Elevated serum levels of TNF soluble receptors in patients with positive anti-neutrophil cytoplasmic antibodies. Br J Rheumatol 1994;33:428-31.
9. Engelberts I, Stephens S, Francot GJ, van der Linden CJ, Buurman WA: Evidence for different effects of soluble TNF receptors on various TNF measurements in human biological fluids. Lancet 1991;338:515-6.
10. Diez-Ruiz A, Tilz GP, Zangerle R, Baier-Bitterlich G, Wachter H, Fuchs D: Soluble receptor for tumor necrosis factor in clinical laboratory diagnosis. Eur J Haematol 1995;54:1-8.
11. Rubin LA: The soluble interleukin-2 receptor in rheumatic disease. Arthritis Rheum 1990;33:1145-8.
12. Wachter H, Fuchs D, Hausen A, Reibnegger G, Werner ER: Neopterin as a marker for the activation of cellular immunity: Immunological basis and clinical application. Adv Clin Chem 1989;27:81-141.
13. Barrera P, Boerbooms AM, Janssen EM: Circulating soluble tumor necrosis factor receptors, interleukin-2 receptors, tumor necrosis factor alpha, and interleukin-6 levels in rheumatoid arthritis. Arthritis Rheum 1993;36:1070-9.
14. Aderka D, Wysenbeek A, Engelmann H, et al: Correlation between serum levels of soluble tumor necrosis factor receptor and disease activity in systemic lupus erythematosus. Arthritis Rheum 1993;36:1111-20.
15. Samsonov MY, Tilz GP, Egorova O, et al: Serum soluble markers of immune activation and disease activity in systemic lupus erythematosus. Lupus 1995;4:29-32.
16. Lim KL, Jones AC, Brown NS, Powell RJ: Urine neopterin as a parameter of disease activity in patients with systemic lupus erythematosus: Comparisons with serum sIL-2R and antibodies to dsDNA, erythrocyte sedimentation rate, and plasma C3, C4, and C3 degradation products. Ann Rheum Dis 1993;52:429-35.
17. Samsonov MY, Tilz GP, Pisklakov VP, et al: Serum soluble receptors for tumor necrosis factor alpha and interleukin-2, and neopterin in acute rheumatic fever. Clin Immunol Immunopathol 1995;74:31-4.
18. Barren KS, Montalvo JF, Joseph AK, et al: Soluble interleukin-2 receptors in children with Kawasaki syndrome. Arthritis Rheum 1990;33:1371-7.
19. Hamzaoui K, Ayed K: Soluble interleukin-2 receptors in patients with Behçet's disease. J Rheumatol 1989;16:852-3.
20. Stegeman CA, Cohen Tervaert JW, Huitema MG, Kallenberg CG: Serum markers of T cell activation in relapses of Wegener's granulomatosis. Clin Exp Immunol 1993;91:415-20.
21. Schmitt WH, Heesen C, Csernok E, Rautmann A, Gross WL: Elevated serum levels of soluble interleukin-2 receptors in patients with Wegener's granulomatosis. Arthritis Rheum 1992;35:1088-96.
22. Huber C, Batchelor JR, Fuchs D, et al: Immune response-associated production of neopterin. Release from macrophages primary under control of interferon-gamma. J Exp Med 1984;160:310-6.
23. Fuchs D, Hausen A, Reibnegger G, Werner ER, Dierich MP, Wachter H: Neopterin as a marker for activated cell-mediated immunity: Application in HIV infection. Immunol Today 1988;9:150-5.
24. Iizuka T, Minatogawa Y, Suzuki H, et al: Urinary neopterin as a predictive marker of coronary artery abnormalities in Kawasaki syndrome. Clin Chem 1993;39:600-4.
25. Nassonov E, Samsonov M, Beketova T, Semenkova L, Wachter H, Fuchs D: Serum neopterin concentrations in Wegener's granulomatosis correlate with vasculitis activity. Clin Exp Rheumatol 1995;13:353-6.
26. Leavitt RY, Fauci AS, Bloch DA, et al: The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritis Rheum 1990;33:1101-7.
27. DeRemee RA, McDonald TJ, Harrison EJ, et al: Wegener's granulomatosis, anatomic correlates, a proposal classification. Mayo Clin Proc 1976;51:777-81.
28. Luqmani RA, Bacon PA, Moots RJ, et al: Birmingham vasculitis activity score (BVAS) in systemic necrotizing vasculitis. Q J Med 1994;87:671-8.
29. Nolle B, Specks U, Ludemann J, et al: Anti-cytoplasmic autoantibodies: Their immunodiagnostic value in Wegener's granulomatosis. Ann Intern Med 1989;111:28-40.
30. Savage CO, Winearls CG, Lones S, et al: Prospective study of radioimmunoassay for antibodies against neutrophil cytoplasm in diagnosis of systemic vasculitis. Lancet 1987;1:1384-93.
31. Highton J, Hessian P: A solid-phase enzyme immunoassay for C-reactive protein: Clinical value and the effects of rheumatoid factor. J Immunol Methods 1984;68:185-92.
32. Deguchi Y, Shibata N: Enhanced expression of the tumor necrosis factor/cachectin gene in peripheral blood mononuclear cells from patients with systemic vasculitis. Clin Exp Immunol 1990;81:311-4.
33. Falk RJ, Terrell RS, Charles LA, Jennette JC: Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc Natl Acad Sci USA 1990;87:4115-9.
34. Porteu F, Nathan C: Mobilizable intracellular pool of p55 (type I) tumor necrosis factor receptors in human neutrophils. J Leukoc Biol 1992;52:122-4.
35. Aderka D, Engelmann H, Maor Y, Brakebusch C, Wallach D: Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med 1992;175:323-9.
36. Mayet WJ, Csernok E, Szymkowiak C, Gross WL, Meyer zum Büschenfelde KH: Human endothelial cells express proteinase 3, target antigen of anticytoplasmic antibodies in Wegener's granulomatosis. Blood 1993;82:1221-9.
37. Mayet WJ, Schwarting A, Meyer zum Büschenfelde KH: Cytotoxic effects of antibodies to proteinase 3 (c-ANCA) on human endothelial cells. Clin Exp Immunol 1994;97:458-65.
38. Mayet WJ, Meyer zum Büschenfelde KH: Antibodies to proteinase 3 increase adhesion of neutrophils to human endothelial cells. Clin Exp Immunol 1993;94:440-6.
39. Savage CO: The endothelial cell: Active participant or innocent bystander in primary vasculitis. Clin Exp Immunol 1993;(suppl 1)93:6-7.
40. Henderson DC, Sheldon J, Riches P, Hobbs JR: Cytokine induction of neopterin production. Clin Exp Immunol 1991;83:479-82.
41. Andert SE, Griesmacher A, Zuckermann A, Müller MM: Neopterin release from human endothelial cells is triggered by interferon-gamma. Clin Exp Immunol 1992;88:555-8.
42. Werner-Felmayer G, Werner ER, Fuchs D, Hausen A, Reibnegger G, Wachter H: Tumor necrosis factor-alpha and lipopolysaccharide enhance interferon-induced tryptophan degradation and pteridine synthesis in human cells. Biol Chem Hoppe Seyler 1989;370:1063-9.
43. Weiss G, Fuchs D, Hausen A, et al: Neopterin modulates toxicity mediated by reactive oxygen and chloride species. FEBS Lett 1993;321:89-92.
44. Holter W, Goldman CK, Casabo L, Nelson DL, Greene WC, Waldmann TA: Expression of functional IL-2 receptors by lipopolysaccharide and interferon-gamma stimulated human monocytes. J Immunol 1987;138:2917-22.
45. Chikanza IC, Roux-Lombard P, Dayer JM, Panayi GS: Tumor necrosis factor soluble receptors behave as acute phase reactants following surgery in patients with rheumatoid arthritis, chronic osteomyelitis and osteoarthritis. Clin Exp Immunol 1993;92:19-22.